South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed "disappointing" results against its new Covid variant. Scientists say the variant accounts for 90% ...

The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...

In observance of World Lung Cancer Day, AstraZeneca has highlighted ... the incidence of lung cancer in various regions of Africa is as follows: South Africa is 27.5 and 9.3, North Africa is ...

Dubai: AstraZeneca, an affiliate of the multinational pharmaceutical and biotechnology company, has been recently achieved the best place to work, best place to work for Women and Best Place to Work ...

Global biopharmaceutical company, AstraZeneca is set to investigate the effectiveness of using artificial intelligence for heart screening.

SEOUL--South Korea has reached a deal with AstraZeneca PLC to purchase its coronavirus vaccine candidate as it seeks to secure supplies amid a resurgence of outbreaks, local media reported on ...

The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Qiagen and AstraZeneca are expanding their diagnostics partnership, with plans to explore the use of genomic profiling in chronic diseases beyond cancer. The long-time collaborators, which ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.